Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies

NCT00003109 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT00003109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
December 31, 1997
Completion date
January 31, 2001
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific